During Tuesday’s trade, Shares of Banco Bilbao Vizcaya Argentaria SA (ADR) (NYSE:BBVA), gained 0.26% to $7.58.
BBVA Compass and alternative credit agency eCredable declared they are teaming up on a pilot program to provide credit cards to “credit invisible” consumers who have been shut out from certain banking services because of their nonexistent or insufficient credit history with the traditional reporting agencies.
eCredable’s AMP Credit Score™ uses other payment history — like rent and utility payments — to prove creditworthiness. The bank will consider the AMP Credit Scores of those who apply through the eCredable website for the BBVA Compass NBA American Express Card. The pilot project underscores BBVA Compass’ drive to work with the industry disruptors who are finding novel ways to serve clients, especially when it means bringing the underserved into the banking system.
“Our mission is to serve our clients and assist them build brighter futures, and sometimes that means from the very ground up,” said BBVA Compass Executive Director of Payments Ryan Kraynick. “Working with eCredable will allow us to meet the needs of a wider spectrum of credit-worthy consumers who for various reasons have not been able to create a traditional credit profile.”
Banco Bilbao Vizcaya Argentaria, S.A. engages in the retail banking, wholesale banking, asset administration, and private banking businesses primarily in Spain, Eurasia, Mexico, South America, and the United States.
Shares of International Business Machines Corp. (NYSE:IBM), inclined 1.88% to $138.42, during its current trading session.
International Business Machines Corp., declared that Afro stream, provider of a niche video streaming service featuring African and African-American content, has deployed solutions from Aspera, an IBM company to speed content delivery to its cloud-based Video on Demand (VOD) platform. The solution unlocks the benefits of the IBM Cloud, streamlining Afro stream’s data-intensive workflow starting with media uploads from studios and content providers through final distribution of African movies and TV shows for streaming by fans across the world.
With offices in the US and France, Afro stream hosts an extensive content library that is presently available to millions of fans in France, Belgium, Switzerland and the Sub-Saharan regions of Senegal and Ivory Coast; additionally, the company has secured rights for many other African countries to bolster its growth in the African VOD space.
To gather quality entertainment for its customer base, Afro stream signed content deals with major studios and independent American, African and British distributors, which submit terabytes of digital content via Aspera to the company’s data center every day.
International Business Machines Corporation provides information technology (IT) products and services worldwide. The company’s Global Technology Services segment provides IT infrastructure and business process services, such as outsourcing, processing, integrated technology, cloud, and technology support. Its Global Business Services segment offers consulting and systems integration services for strategy and transformation, application innovation services, enterprise applications, and smarter analytics; and application administration, maintenance, and support services.
Finally, Intrexon Corp (NYSE:XON), gained 1.56%, and is now trading at $30.03.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company’s synthetic immuno-oncology programs, in partnership with Intrexon Corporation (XON) and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use non-viral gene transfer methods for broad scalability.
ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, declared that it will host a conference call and webcast slide presentation on Wednesday, December 16, 2015 at 4:30 PM ET to provide a corporate update and discuss the Company’s 2016 outlook.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
